Edition:
United Kingdom

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.68USD
6:08pm GMT
Change (% chg)

$0.02 (+3.03%)
Prev Close
$0.66
Open
$0.66
Day's High
$0.68
Day's Low
$0.65
Volume
27,824
Avg. Vol
108,148
52-wk High
$1.43
52-wk Low
$0.44

Select another date:

Wed, Jan 17 2018

BRIEF-Aviragen Therapeutics Says Digirad & East Hill Indicated Intention To Nominate 11 Candidates To Co's Board

* AVIRAGEN THERAPEUTICS - CONFIRMED IT RECEIVED NOTICE FROM DIGIRAD & EAST HILL MANAGEMENT INDICATING INTENTION TO NOMINATE 11 CANDIDATES TO CO'S BOARD Source text for Eikon: (http://bit.ly/2Df8Div) Further company coverage:

BRIEF-Thomas Clay Reports A 8.3 Pct Stake In Aviragen Therapeutics

* THOMAS CLAY REPORTS A 8.3 PCT STAKE IN AVIRAGEN THERAPEUTICS INC AS OF DEC 29 - SEC FILING

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA

BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction

* SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing

BRIEF-Aviragen Therapeutics Q1 loss per share $0.14

* Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results

BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated

* On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing

BRIEF-Aviragen Therapeutics and Vaxart enter into merger agreement

* Aviragen Therapeutics and Vaxart enter into merger agreement

BRIEF-Aviragen Therapeutics reports Q4 loss per share $0.15

* Aviragen therapeutics reports fourth quarter and fiscal year 2017 financial results

Select another date: